Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer’s Disease

• Published in: The journal of prevention of Alzheimer's disease Vol. 11; no. 4; pp. 869 - 873
• Main Authors: Shirzadi, Zahra, Schultz, A. P., Properzi, M., Yaari, R., Yau, W.-Y. W., Brickman, A. M., Rafii, M. S., Donohue, M. C., Ernstrom, K., Wang, S., Jack, C. R., Greenberg, S. M., Raman, R., Aisen, P., Sperling, R. A., Chhatwal, J. P.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 2024
• Subjects: Aged; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Antibodies, Monoclonal, Humanized - therapeutic use; Double-Blind Method; Female; Geriatrics/Gerontology; Humans; Magnetic Resonance Imaging; Male; Medicine; Medicine & Public Health; Neurology; Original Research; Prodromal Symptoms; White Matter - diagnostic imaging; White Matter - drug effects; White Matter - pathology; preclinical AD; White matter hyperintensity; cerebral amyloid angiopathy; microhemorrhages; amyloid related imaging abnormalities
• ISSN: 2426-0266
• DOI: 10.14283/jpad.2024.139

Background Increased white matter hyperintensity (WMH) volume visible on MRI is a common finding in Alzheimer’s disease (AD). We hypothesized that WMH in preclinical AD is associated with the presence of advanced vessel amyloidosis manifested as microhemorrhages (MCH). Objectives 1) To assess the relationship between baseline WMH volume and baseline MCH. 2) To assess the relationship between longitudinal WMH accumulation and last MRI MCH during the double-blind phase of the A4 trial. Design A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study comparing solanezumab with placebo given as infusions once every 4 weeks over 4.5 years in subjects with preclinical AD, defined as having evidence of elevated brain amyloid before the stage of clinically evident cognitive impairment, with an optional open-label extension period. Setting Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study. Participants A sample of 1157 cognitively unimpaired older adults (mean age = 71.9 years [SD = 4.8 years], 59% women, 59% APOE ε4 carriers). Measurements A linear regression model was used to assess the impact of baseline MCH amount (0, 1, 2+) on WMH volume. A linear mixed-effects model was used to assess the impact of last MRI MCH on longitudinal WMH. All models were corrected for age, sex, grey matter volume, cortical amyloid PET, APOE ε4 status, and treatment group. Results Baseline WMH volume was greater in individuals with more than one MCH compared to those with no MCH (t=4.8, p<0.001). The longitudinal increase in WMH amongst individuals with one (t=2.3, p=0.025) and more than one MCH (t=6.7, p<0.001) at the last MRI was greater than those with no MCH. Conclusion These results indicate a strong association between WMH and MCH, a common manifestation of cerebral amyloid angiopathy and ARIA-H. These results suggest that increased WMH volume may represent an early sign of vessel amyloidosis, likely prior to the emergence of MCH.